Overcoming Target Driven Fratricide for T Cell Therapy

Overview
Investigated methods to overcome fratricide in NKG2D-CAR T cell production. The manufacturing process included an expansion phase in G-Rex® containers, which was part of the upscaling strategy to produce sufficient cell yields.
What this paper found
NKG2D-CAR T cells (NKR-2) undergo target-driven fratricide during manufacture, and both a PI3K inhibitor and an anti-NKG2D blocking antibody limit it, with the antibody giving the better cell yield. In an initial experiment, expansion was 2.6-fold without blockade and 13.8-fold with the antibody. The inhibitor LY294002 lowered surface NKG2D to control levels at 10 μM and improved viability after cryopreservation, but yields stayed poor and it reduced proliferation of control T cells. Adding the antibody on day 6 instead of day 4 gave a CD4/CD8 ratio similar to the inhibitor process, with expansion comparable to control T cells and comparable cytokine secretion and cytolytic activity against PANC-1 cells. In a preliminary mouse AML (THP-1) model both processes showed similar antitumor activity.
Note: The mouse antitumor and engraftment comparison was a preliminary experiment, and several supporting data are reported as not shown.
By means of targeted inhibition of NKG2D expression or generic inhibition of enzyme function, target-driven CAR T fratricide can be overcome. — Eytan Breman, Benjamin Demoulin, Sophie Agaugué, Sebastien Mauën, Alexandre Michaux, Lorraine Springuel, Julien Houssa, Fanny Huberty, Céline Jacques-Hespel, Céline Marchand, Jérôme Marijsse, Thuy Nguyen, Nancy Ramelot, Benjamin Violle, Dorothée Daro, Peter De Waele, David E. Gilham, Valérie Steenwinckel, Frontiers in Immunology
Study details
- Authors
- Eytan Breman, Benjamin Demoulin, Sophie Agaugué, Sebastien Mauën, Alexandre Michaux, Lorraine Springuel, Julien Houssa, Fanny Huberty, Céline Jacques-Hespel, Céline Marchand, Jérôme Marijsse, Thuy Nguyen, Nancy Ramelot, Benjamin Violle, Dorothée Daro, Peter De Waele, David E. Gilham, Valérie Steenwinckel
- Institution
- Celyad S.A., Mont-Saint-Guibert, Belgium
- Journal
- Frontiers in Immunology
- Year
- 2018
- G-Rex® model(s)
- G-Rex®10
- Cell type(s)
- CAR T Cells
- Application area
- Hematologic malignancy · Solid tumor
- Study phase
- Preclinical
How G-Rex® was used
Healthy-donor PBMC were activated for 2 days with OKT3 and IL-2, transduced in 24-well retronectin-coated plates for 2 days, then washed and transferred to G-Rex® containers (catalog 80040S) for a 4-day expansion phase. Cells were grown in complete X-Vivo 15 medium with serum and IL-2 at 100 IU/mL, with LY294002 or anti-NKG2D antibody added during expansion in the fratricide-control processes. Fold expansion was measured against the initial seeding density at harvest; untreated NKR-2 cells expanded 2.6-fold versus 13.8-fold with antibody blockade.
Explore related
Full citation
Breman E, Demoulin B, Agaugué S, et al. Overcoming Target Driven Fratricide for T Cell Therapy. Front Immunol. 2018;9:2940.
Building a similar workflow?
Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.